Imutec Corp. announced Monday its plans for a series of PhaseIII clinical trials on its drug Virulizin.

The Toronto company intends to run randomized, controlledPhase III trials on Virulizin for treating advanced pancreaticcancer at the Montreal General Hospital; for treating advancedmalignant melanoma at the National Cancer Institute in MexicoCity; and for treating advanced cervico-uterine cancer, also inMexico.

Imutec (NASDAQ:IMUTF) expects to file investigational newdrug (IND) protocol submissions for these trials soon.

(c) 1997 American Health Consultants. All rights reserved.